Metacrine Stock

metacrine.comHealthcareFounded: 2014Funding to Date: $134.77MM

Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases.

Register for Details

For more details on financing and valuation for Metacrine, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Metacrine.

Register Today

Team

Management Team

Trisha Millican
Chief Financial Officer
Karl Cremer
Vice President, Clinical Operations
Michael Downes
Co-Founder
Kathie Huynh
Executive
Hubert Chen MD
Chief Medical Officer
Richard Heyman Ph.D
Co-Founder & Chairman
Nicholas Smith Ph.D
Senior Vice President, Chemistry
Eric Bischoff
Vice President, Development and Business Operations
Ken Song MD
President, Chief Executive Officer & Board Director

Board Members

Amir Nashat Ph.D
Polaris Partners
Richard Heyman Ph.D
Carol Gallagher
New Enterprise Associates
Kristina Burow
ARCH Venture Partners
Ronald Evans Ph.D
Andrew Guggenhime
Ken Song MD
Robert Adelman MD
venBio

Other companies like Metacrine in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$396.01MM
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$1.53B

News

SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and...
Metacrine, Inc., a San Diego, CA-based innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, completed a $65m Series C financing
Updated on: Jun 4, 2023